Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Study tests new drug combo against standard chemo for tough ovarian cancers

NCT ID NCT06964165

Summary

This study aimed to compare two different drug treatments given before surgery for advanced ovarian cancer. Researchers tested whether a newer targeted drug called niraparib worked better than standard platinum-taxane chemotherapy for patients with specific genetic features in their tumors. The trial involved 36 participants with stage III or IV ovarian cancer and was terminated early.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN NEOPLASMS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • GSK Investigational Site

    San Francisco, California, 94115, United States

  • GSK Investigational Site

    Miami, Florida, 33136, United States

  • GSK Investigational Site

    Tampa, Florida, 33606, United States

  • GSK Investigational Site

    Scarborough, Maine, 04074, United States

  • GSK Investigational Site

    Boston, Massachusetts, 02114, United States

  • GSK Investigational Site

    St Louis, Missouri, 63141, United States

  • GSK Investigational Site

    New York, New York, 10029, United States

  • GSK Investigational Site

    New York, New York, 77030, United States

  • GSK Investigational Site

    Rochester, New York, 14642, United States

  • GSK Investigational Site

    Sioux Falls, South Dakota, 57105, United States

  • GSK Investigational Site

    Seattle, Washington, 98104, United States

  • GSK Investigational Site

    Ottawa, Ontario, K1H 8L6, Canada

  • GSK Investigational Site

    Montreal, Quebec, H2X 0A9, Canada

  • GSK Investigational Site

    Montreal, Quebec, H4A 3J1, Canada

  • GSK Investigational Site

    A Coruña, ES, 15006, Spain

  • GSK Investigational Site

    Madrid, ES, 28027, Spain

  • GSK Investigational Site

    Madrid, ES, 28033, Spain

  • GSK Investigational Site

    Madrid, ES, 28050, Spain

  • GSK Investigational Site

    Madrid, ES, 28223, Spain

  • GSK Investigational Site

    Málaga, ES, 29001, Spain

  • GSK Investigational Site

    Pamplona, ES, 31008, Spain

Conditions

Explore the condition pages connected to this study.